REGISTERED NUMBER: 12370221 (England and Wales)

Unaudited Financial Statements For The Year Ended 31st March 2025

for

GENETECH PHARMACEUTICALS LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTOR:

L H Lowrie

SECRETARY:

Mrs E Lowrie

REGISTERED OFFICE:

Unit 3, Enterprise Business Centre,

Consul Avenue

Rainham

RM13 8JE

REGISTERED NUMBER:

12370221 (England and Wales)

ACCOUNTANTS:

Dua & Co. Limited

1st Floor

5 Century Court

Tolpits Lane

Watford

Hertfordshire

WD18 9PX

FIXED ASSETS

Property, plant and equipment

4

16,918

15,789

CURRENT ASSETS

Inventories

1,586,997

900,042

Debtors

5

662,386

1,049,719

Cash at bank

671,698

552,474

2,921,081

2,502,235

CREDITORS

Amounts falling due within one year

6

2,223,577

2,161,641

NET CURRENT ASSETS

697,504

340,594

TOTAL ASSETS LESS CURRENT LIABILITIES

714,422

356,383

CAPITAL AND RESERVES

Called up share capital

120

120

Retained earnings

714,302

356,263

714,422

356,383

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 23rd December 2025 and were signed by:

L H Lowrie - Director

1.	STATUTORY INFORMATION

GENETECH PHARMACEUTICALS LIMITED is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery

-

25% on reducing balance

Fixtures and fittings

-

20% on reducing balance

Computer equipment

-

25% on reducing balance

Stocks

Inventories are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 8 (2024 - 8 ) .

4.	PROPERTY, PLANT AND EQUIPMENT

Plant and

machinery

etc

£

COST

At 1st April 2024

35,584

Additions

6,086

At 31st March 2025

41,670

DEPRECIATION

At 1st April 2024

19,795

Charge for year

4,957

At 31st March 2025

24,752

NET BOOK VALUE

At 31st March 2025

16,918

At 31st March 2024

15,789

5.

DEBTORS

2025

2024

£

£

Amounts falling due within one year:

Trade debtors

441,510

976,076

Other debtors

211,511

64,278

653,021

1,040,354

Amounts falling due after more than one year:

Other debtors

9,365

9,365

Aggregate amounts

662,386

1,049,719

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Payments on account

193,438

241,020

Trade creditors

1,673,267

1,649,411

Taxation and social security

196,386

46,131

Other creditors

160,486

225,079

2,223,577

2,161,641